Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jimi | - |
dc.date.accessioned | 2024-02-15T01:30:19Z | - |
dc.date.available | 2024-02-15T01:30:19Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90414 | - |
dc.description.abstract | Activating mutations in KRAS are highly relevant to various cancers, driving persistent efforts toward the development of drugs that can effectively inhibit KRAS activity. Previously, KRAS was considered 'undruggable'; however, the recent advances in our understanding of RNA and nucleic acid chemistry and delivery formulations have sparked a paradigm shift in the approach to KRAS inhibition. We are currently witnessing a large wave of next-generation drugs for KRAS mutant cancers-nucleic acid-based therapeutics. In this review, we discuss the current progress in targeting KRAS mutant tumors and outline significant developments in nucleic acid-based strategies. We delve into their mechanisms of action, address existing challenges, and offer insights into the current clinical trial status of these approaches. We aim to provide a thorough understanding of the potential of nucleic acid-based strategies in the field of KRAS mutant cancer therapeutics. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers | - |
dc.type | Article | - |
dc.identifier.wosid | 001116093800001 | - |
dc.identifier.doi | 10.3390/ijms242316933 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, no.23 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85179365199 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 24 | - |
dc.citation.number | 23 | - |
dc.type.docType | Review | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | oncogenic KRAS | - |
dc.subject.keywordAuthor | cancer therapy | - |
dc.subject.keywordAuthor | RNA therapeutics | - |
dc.subject.keywordAuthor | RNAi | - |
dc.subject.keywordAuthor | CRISPR-Cas | - |
dc.subject.keywordAuthor | mRNA vaccine | - |
dc.subject.keywordPlus | ONCOGENIC KRAS | - |
dc.subject.keywordPlus | MESSENGER-RNA | - |
dc.subject.keywordPlus | COVALENT INHIBITOR | - |
dc.subject.keywordPlus | TARGETING KRAS | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | RAS | - |
dc.subject.keywordPlus | RECOGNITION | - |
dc.subject.keywordPlus | VACCINES | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | OLIGONUCLEOTIDES | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.